Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook

Laiba Immad

Tue, May 19, 2026 at 7:10 AM EDT 2 min read

We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Medicus Pharma Ltd. (NASDAQ:MDCXW) is one of the best penny stocks on this list.

TheFly reported on May 14 that MDCXW announced its financial results for the three months ended March 31, 2026, along with a detailed corporate update across its development programs. The corporation reported progress in its Teverelix program, including FDA clearance to proceed with a Phase 2b dose-optimization study in advanced prostate cancer and submission of additional protocols targeting urinary retention in benign prostatic hyperplasia.

The company’s strategic updates included expanded financing capacity through ATM arrangements and continued evaluation of partnerships and acquisitions. Financial results showed cash and cash equivalents of $6.4 million, operating expenses of $8.6 million, and a net loss of $9.0 million, alongside higher R&D spending. The company reiterated ongoing capital access and multiple anticipated clinical milestones for 2026.

Other than that, earlier on May 6, Medicus Pharma Ltd. (NASDAQ:MDCXW) reported updated findings from an expanded Phase 2 SKNJCT-003 analysis evaluating a doxorubicin microneedle array for nodular basal cell carcinoma. The dataset included 69 participants and showed a clear dose-dependent response, with the highest dose group demonstrating the strongest histological and clinical clearance outcomes by day 57 compared with the control.

Safety results indicated a favorable tolerability profile, with no treatment-related serious adverse events or evidence of systemic toxicity. The company stated that these findings further support a potential registrational pathway and upcoming discussions with regulators regarding the late-stage development strategy.

Medicus Pharma Ltd. (NASDAQ:MDCXW) is a clinical-stage biotechnology company based in Toronto and Pennsylvania. It develops and advances therapies for high-need diseases, with a focus on oncology and prostate cancer.

While we acknowledge the potential of MDCXW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Most Oversold Large Cap Stocks to Buy and 10 Best Cancer Stocks to Buy for the Long Term. 

Disclosure: None. Follow Insider Monkey on Google News.